Jeffrey Adam Novack, the Secretary and General Counsel of CareDx, Inc., has reported a transaction involving 2,873 shares of the company’s common stock. This transaction, which took place on November 1, 2026, is significant as it pertains to tax withholding obligations associated with the vesting of restricted stock units.

CareDx, Inc. operates in the medical laboratories sector, focusing on specialized services related to transplant diagnostics and monitoring. The company is incorporated in Delaware and has its business address at 8000 Marina Boulevard, 4th Floor, Brisbane, California.

The recent filing, accession number 0002019976-26-000013, indicates that Novack acquired the shares, which were withheld to satisfy tax obligations. Following this transaction, he now owns a total of 102,205 shares in CareDx.

Novack's role as an officer at CareDx means that this transaction may have implications for investor perceptions regarding executive compensation and stock ownership transparency. The filing does not specify any further actions or upcoming events related to this transaction.

Details were not available in the SEC filing regarding future plans or additional transactions.

In the transaction reported, Novack's shares were withheld at a price of $85.88 per share, which reflects the company's stock value at the time of the transaction. This withholding was specifically to meet tax obligations arising from the vesting of restricted stock units, a common practice among executives to manage tax liabilities efficiently.

Additionally, the filing indicates that Novack's total ownership in CareDx, Inc. now stands at 102,205 shares, all of which are directly owned. This level of ownership may influence his alignment with shareholder interests and the company's performance.

CareDx, Inc. is classified under the Standard Industrial Classification (SIC) code 8071, which pertains to medical laboratories, highlighting its focus on providing specialized diagnostic services.

The filing does not provide information about any other executive transactions, stock option grants, or changes in company leadership that may affect shareholder dynamics.